Chemical: Drug
desloratadine
PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.
Annotated Labels
- Annotation of FDA Label for desloratadine
- Annotation of EMA Label for desloratadine
1. Annotation of FDA Label for desloratadine
Summary
Desloratadine and psuedoephidrine is used to treat nasal congestion and other symptoms of seasonal allergic rhinitis. The label does not specify any protein or gene names associated with variation in metabolism. This drug-biomarker pair was previously in the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" but has subsequently been removed.
Annotation
The FDA-approved drug label for desloratadine and psuedoephedrine (Clarinex-D) highlighted information regarding variation in the metabolism of desloratadine. This drug-biomarker pair was previously in the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" but has subsequently been removed.
The label mentioned that "poor metabolizers" had a decreased ability to form 3-hydroxydesloratadine and a 6-fold greater median exposure (AUC) to desloratadine. Though no overall differences in safety were observed between poor metabolizers and normal metabolizers, the label noted that an increased risk of exposure-related adverse events in poor metabolizers cannot be ruled out. However, the label did not specify any protein or gene names associated with the variation in metabolism efficacy, therefore it is unclear from the label which enzyme has these "poor metabolizers" of desloratidine.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the desloratadine and pseudoephedrine drug label.
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.
Genes and/or phenotypes found in this label
-
Rhinitis, Allergic, Seasonal
- source: U.S. Food and Drug Administration
2. Annotation of EMA Label for desloratadine
Summary
The EMA European Public Assessment Report (EPAR) highlights information regarding variation in the metabolism of desloratadine in different individuals, but does not mention pharmacogenetics or genetic testing. The genes/ enzymes involved are not known.
Annotation
Excerpt from the Desloratadine and Pseudoephedrine (Aerinaze) EPAR:
"In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metabolizer phenotype was greater among Blacks adults than Caucasians adults (18 % vs. 2 %) however the safety profile of these subjects was not different from that of the general population. In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours."
This information is highlighted in the following sections:
Pharmacokinetic properties.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Desloratadine and Pseudoephedrine EMA drug label.
*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.
Links in the "Gene" column lead to PharmGKB Gene Pages.
List of all variant annotations for desloratadine
| Gene ? |
Variant?
(147) |
Alternate Names ? | Chemicals ? |
Alleles
?
(+ chr strand) |
Function ? |
Amino Acid?
Translation |
|
|---|---|---|---|---|---|---|---|
| rs10908703 | NC_000001.10:g.159252002G>A, NC_000001.11:g.159282212G>A, NM_002001.3:c.-1782G>A, rs59154953 |
G > A
|
SNP | ||||
| rs2298805 | NC_000001.10:g.159273943G>A, NC_000001.11:g.159304153G>A, NM_002001.3:c.302G>A, NP_001992.1:p.Ser101Asn, XM_005244956.1:c.311G>A, XP_005245013.1:p.Ser104Asn, rs52799204, rs56423676 |
G > A
|
SNP |
S101N
|
|||
| rs2494262 | NC_000001.10:g.159253672C>A, NC_000001.11:g.159283882C>A, NM_002001.3:c.-112C>A, rs17673238, rs59461022 |
C > A
|
SNP |
Overview
- Descarboethoxyloratadine
- Descarboethoxyoratidine
- Desloratidine
- desloratadine
- Aerius
- Claramax
- Clarinex
- Clarinex Reditabs
- NeoClarityn
- Clarinex-D 12 Hour Extended Release Tablets (desloratadine + pseudoephedrine)
- Desloratadine and Pseudoephedrine (Aerinaze)
PharmGKB Accession Id
PA164776964
Type(s):
Drug
Description
Source: Drug Bank
Indication
Source: Drug Bank
Other Vocabularies
- MeSH: desloratadine (C121345)
- ATC: Other antihistamines for systemic use (R06AX)
- UMLS: desloratadine (C0908935)
- RxNorm: desloratadine (275635)
- NDFRT: DESLORATADINE (N0000148729)
Information pulled from DrugBank has not been reviewed by PharmGKB.
Pharmacology, Interactions, and Contraindications
Mechanism of Action
Source: Drug Bank
Pharmacology
Source: Drug Bank
Absorption, Distribution, Metabolism, Elimination & Toxicity
Route of Elimination
Source: Drug Bank
Chemical Properties
Isomeric SMILES
Source: Drug Bank
Source: Drug Bank
SMILES
ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1
Source: Drug Bank
InChI String
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
Source: Drug Bank
Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.
Curated Information ?
Drug Targets
| Gene | Description |
|---|---|
| HRH1 | (source: Drug Bank ) |
Curated Information ?
| Evidence | Disease |
|---|---|
| Rhinitis, Allergic, Seasonal | |
| Urticaria |
Relationships from National Drug File - Reference Terminology (NDF-RT)
May Treat
- desloratadine may treat Rhinitis, Allergic, Perennial
- desloratadine may treat Urticaria
Contraindicated With
- desloratadine contraindicated with Drug Hypersensitivity
Publications related to desloratadine: 2
Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients. Archives of dermatological research. 2015. Guo Aiyuan, et al.
|
|
|
Metabolism of loratadine and further characterization of its in vitro metabolites. Drug metabolism letters. 2009. Ghosal Anima, et al.
|
LinkOuts
- Web Resource:
- Wikipedia
- National Drug Code Directory:
- 0085-1264-01
- DrugBank:
- DB00967
- Drugs Product Database (DPD):
- 2243919
- BindingDB:
- 50073179
- ChemSpider:
- 110575
- Therapeutic Targets Database:
- DAP000331
- FDA Drug Label at DailyMed:
- 5b79aff4-9bed-429d-8def-a7929293387d
Clinical Trials
These are trials that mention desloratadine and are related to either pharmacogenetics or pharmacogenomics.
NURSA Datasets
No NURSA datasets available.